DB:1FW

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

WuXi Biologics (Cayman) Inc., an investment holding company, operates as an open-access technology platform company that provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People’s Republic of China and internationally.


Snowflake Analysis

Flawless balance sheet with high growth potential.


Similar Companies

Share Price & News

How has WuXi Biologics (Cayman)'s share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1FW has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-6.0%

1FW

-0.7%

DE Life Sciences

3.2%

DE Market


1 Year Return

66.3%

1FW

50.7%

DE Life Sciences

0.01%

DE Market

Return vs Industry: 1FW exceeded the German Life Sciences industry which returned 49% over the past year.

Return vs Market: 1FW exceeded the German Market which returned 0.3% over the past year.


Shareholder returns

1FWIndustryMarket
7 Day-6.0%-0.7%3.2%
30 Day-2.1%8.4%4.7%
90 Day6.9%25.3%-0.9%
1 Year66.3%66.3%51.6%50.7%1.7%0.01%
3 Yearn/a103.6%99.3%-6.8%-14.0%
5 Yearn/a258.4%235.1%3.9%-9.5%

Price Volatility Vs. Market

How volatile is WuXi Biologics (Cayman)'s share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is WuXi Biologics (Cayman) undervalued compared to its fair value and its price relative to the market?

137.04x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 1FW (€14) is trading above our estimate of fair value (€6.23)

Significantly Below Fair Value: 1FW is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 1FW is poor value based on its PE Ratio (137x) compared to the Life Sciences industry average (62.6x).

PE vs Market: 1FW is poor value based on its PE Ratio (137x) compared to the German market (18.5x).


Price to Earnings Growth Ratio

PEG Ratio: 1FW is poor value based on its PEG Ratio (4.5x)


Price to Book Ratio

PB vs Industry: 1FW is overvalued based on its PB Ratio (11.4x) compared to the XE Life Sciences industry average (5x).


Next Steps

Future Growth

How is WuXi Biologics (Cayman) forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

30.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 1FW's forecast earnings growth (30.6% per year) is above the savings rate (0.2%).

Earnings vs Market: 1FW's earnings (30.6% per year) are forecast to grow faster than the German market (21.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 1FW's revenue (24.2% per year) is forecast to grow faster than the German market (5.7% per year).

High Growth Revenue: 1FW's revenue (24.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 1FW's Return on Equity is forecast to be low in 3 years time (16.9%).


Next Steps

Past Performance

How has WuXi Biologics (Cayman) performed over the past 5 years?

52.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1FW has a high level of non-cash earnings.

Growing Profit Margin: 1FW's current net profit margins (25.4%) are higher than last year (24.9%).


Past Earnings Growth Analysis

Earnings Trend: 1FW's earnings have grown significantly by 52.3% per year over the past 5 years.

Accelerating Growth: 1FW's earnings growth over the past year (60.8%) exceeds its 5-year average (52.3% per year).

Earnings vs Industry: 1FW earnings growth over the past year (60.8%) exceeded the Life Sciences industry 13.4%.


Return on Equity

High ROE: 1FW's Return on Equity (7.8%) is considered low.


Next Steps

Financial Health

How is WuXi Biologics (Cayman)'s financial position?


Financial Position Analysis

Short Term Liabilities: 1FW's short term assets (CN¥9.7B) exceed its short term liabilities (CN¥2.9B).

Long Term Liabilities: 1FW's short term assets (CN¥9.7B) exceed its long term liabilities (CN¥1.8B).


Debt to Equity History and Analysis

Debt Level: 1FW's debt to equity ratio (14.7%) is considered satisfactory.

Reducing Debt: 1FW's debt to equity ratio has reduced from 15.2% to 14.7% over the past 5 years.

Debt Coverage: 1FW's debt is well covered by operating cash flow (63.5%).

Interest Coverage: 1FW earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is WuXi Biologics (Cayman)'s current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1FW's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 1FW's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1FW's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1FW's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1FW's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Chris Chen (46yo)

4.33yrs

Tenure

CN¥25,196,000

Compensation

Dr. Zhisheng Chen, also known as Chris, has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr. Chen i ...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD3.53M) is below average for companies of similar size in the German market ($USD5.24M).

Compensation vs Earnings: Chris's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ge Li
Founder & Chairman6.17yrsno datano data
Zhisheng Chen
CEO & Executive Director4.33yrsCN¥25.20m0.093% CN¥17.1m
Weichang Zhou
Executive VP4yrsCN¥5.62mno data
Christine Lu-Wong
Chief Financial Officer4.33yrsno datano data
Jijie Gu
Executive VP & Chief Scientific Officerno datano datano data
Zhiling Ji
Head of Legal Departmentno datano datano data
Jing Li
Senior Vice President of Discovery Service3.58yrsno datano data
Jian Dong
Senior Vice President of Global Biomanufacturing1.92yrsno datano data
Chiang Syin
Senior VP & Chief Quality Officer2.33yrsno datano data
Yue Huang
Joint Company Secretary1.5yrsno datano data

3.5yrs

Average Tenure

52.5yo

Average Age

Experienced Management: 1FW's management team is considered experienced (3.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ge Li
Founder & Chairman6.17yrsno datano data
Zhisheng Chen
CEO & Executive Director4.33yrsCN¥25.20m0.093% CN¥17.1m
Weichang Zhou
Executive VP4yrsCN¥5.62mno data
Peter Schultz
Chair of Scientific Advisory Board2.33yrsno datano data
Wo Fong
Independent Non-Executive Director3yrsCN¥385.00kno data
Edward Hu
Non-Executive Director6.17yrsCN¥187.00k0.055% CN¥10.1m
William Keller
Independent Non-Executive Director3yrsCN¥391.00kno data
Teh Ming Kwauk
Independent Non-Executive Director3yrsCN¥396.00kno data
Yanling Cao
Non-Executive Director4yrsno datano data
Yibing Wu
Non-Executive Director4yrsno datano data

4.0yrs

Average Tenure

55.5yo

Average Age

Experienced Board: 1FW's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 1FW insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.


Top Shareholders

Company Information

WuXi Biologics (Cayman) Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: WuXi Biologics (Cayman) Inc.
  • Ticker: 1FW
  • Exchange: DB
  • Founded: 2014
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$158.473b
  • Listing Market Cap: HK$18.388b
  • Shares outstanding: 1.30b
  • Website: https://www.wuxibiologics.com.cn

Number of Employees


Location

  • WuXi Biologics (Cayman) Inc.
  • No. 108, Meiliang Road
  • Mashan
  • Wuxi
  • Jiangsu Province
  • 214092
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
2269SEHK (The Stock Exchange of Hong Kong Ltd.)YesOrdinary SharesHKHKDJun 2017
1FWDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJun 2017
WXIB.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJun 2017
WXXW.YOTCPK (Pink Sheets LLC)UNSPONSORD ADRUSUSDSep 2017

Biography

WuXi Biologics (Cayman) Inc., an investment holding company, operates as an open-access technology platform company that provides solutions to organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing in the People’s Republic of China and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology; international sales contracting services; testing and development of testing technologies; provision of biologics clinical and manufacturing services provision of sales and marketing services in the United States; production and sales of medicals; vaccine CDMO and related business; and material supplier activities. In addition, it provides clinical and commercial manufacturing, assay, formulation and process development, process validation, lot release testing, stability studies, drug product formulation, fill and finish, and regulatory support services for recombinant protein, monoclonal antibodies, and antibody drug conjugates. The company serves pharmaceutical and biotechnology companies. It has a strategic partnerships with Amicus Therapeutics; ABL Bio; NBE-Therapeutics; I-Mab Biopharma; NovoCodex Biopharmaceuticals Co., Ltd.; and Almirall. The company was founded in 2014 and is headquartered in Wuxi, China. WuXi Biologics (Cayman) Inc. is a subsidiary of WuXi Biologics Holdings Limited. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/05/30 01:07
End of Day Share Price2020/05/29 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.